While, in general, patients with renal and metastatic colon cancer respond well to anti-VEGF therapy, the approval of bevacizumab for breast cancer treatment was suspended in the US after two studies showed contradictory results (reviewed by ref. [8]). The gene discussed is VEGFA; the disease is breast carcinoma.